Vir Biotechnology 2026: Revenue ($188K), Net income ($96.25M), EPS ($0.57) — 10-Q Summary
Vir Biotechnology reported 2026 Q3 revenue of ($188K), a net loss of ($96.25M), and a diluted loss per share of ($0.57). This compares to revenue of $240K, a net loss of ($163.14M), and a diluted loss per share of ($1.17) in the prior-year period. The company is conducting clinical trials for several treatments, including ECLIPSE for CHD, with results expected in 2026-2027. Vir also has agreements with Gilead for solid-tumor T-cell engagers.
How this was made
The 30-second read
Why it matters
The disclosed numbers are the first public release of the quarter's performance, providing fresh data for valuation models.
Market read
Primary disclosure of quarterly results for a micro‑cap biotech; modest relevance to traders focused on earnings and pipeline developments.
What to watch
Upcoming ECLIPSE trial readouts could dominate future price moves more than this quarterly loss.
Background
Vir Biotechnology filed a 10‑Q for the quarter ending 2026, reporting revenue, net loss, and EPS figures, plus updates on its pipeline programs.
Ticker impact
Vir Biotechnology disclosed its 2026 Q4 revenue of $188K and a net loss of $96.25M in its 10‑Q filing.
likely modest upside as investors price in the loss narrowing
First disclosure of the quarterly results; loss narrowed 41% YoY, which could attract value‑seeking traders.
Market effects
Biotech sector may see slight sentiment lift from a loss‑narrowing story, but overall sector remains volatile.
US biotech investors may adjust positions; limited broader market effect.
Minimal global impact beyond niche biotech investors.
Counterpoint
Despite loss narrowing, the company remains cash‑burn heavy; risk‑averse traders may stay short.
Key entities
- companyVir Biotechnology
US‑listed biotech firm (ticker VIR) reporting quarterly results.
